{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:24:00Z","timestamp":1793125440132,"version":"4.5.0"},"reference-count":60,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Infection with varicella zoster virus typically occurs in children and it can cause primary varicella infection or \u201cchickenpox\u201d, or it can reactivate later in life and cause herpes zoster or \u201cshingles\u201d. Herpes zoster mainly occurs in older adults, causing a reduction in activities of daily living, impacting quality of life, and may lead to serious complications, including chronic pain. Two vaccines are marketed to prevent herpes zoster: the live zoster vaccine and the non-live, recombinant zoster vaccine. The pre-licensure clinical trials show the efficacy of the live zoster vaccine to be between 50 and 70% and for the recombinant vaccine to be higher at 90 to 97%. Real-world effectiveness studies, with a follow-up of approximately 10 years, were reviewed in this article. These data corroborated the efficacy studies, with vaccine effectiveness being 46% and 85% for the live and recombinant vaccines, respectively. Safety data from the effectiveness studies show similar results to the clinical trials with mostly local injection-site reactions and mild systemic reactions seen with both vaccines, although in larger proportions with the recombinant vaccine. Rare adverse events, occurring less than 1% of the time, have been seen with both vaccine types and include disseminated herpes zoster with the live zoster vaccine and Guillain\u2013Barr\u00e9 syndrome with the recombinant vaccine. The wider use of preventative measures with vaccines will reduce the herpes zoster burden of illness seen in older adults.<\/jats:p>","DOI":"10.3390\/v14122667","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T04:05:24Z","timestamp":1669781124000},"page":"2667","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines"],"prefix":"10.3390","volume":"14","author":[{"given":"Yasmin","family":"Marra","sequence":"first","affiliation":[{"name":"Faculty of Arts and Sciences, Queen\u2019s University, Kingston, ON K7L 3N6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1266-1901","authenticated-orcid":false,"given":"Fawziah","family":"Lalji","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC V6T 1Z3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJM198312013092205","article-title":"Varicella and herpes zoster: Changing concepts of the natural history, control, and importance of a not-so-benign virus","volume":"309","author":"Weller","year":"1983","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJMcp1302674","article-title":"Clinical practice: Herpes zoster","volume":"369","author":"Cohen","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_3","unstructured":"WHO (2022, October 20). SAGE Working Group on Varicella and Herpes Zoster Vaccines. Available online: https:\/\/www.who.int\/groups\/strategic-advisory-group-of-experts-on-immunization\/working-groups\/varicella-and-herpes-zoster-vaccines-(may-2012---june-2014)."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Arvin, A., and Gershon, A. (2000). Clinical manifestations of herpes zoster. Varicella Zoster Virus: Virology and Clinical Management, Cambridge University Press.","DOI":"10.1017\/CBO9780511601194"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1086\/510206","article-title":"Recommendations for the Management of Herpes Zoster","volume":"44","author":"Dworkin","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jpain.2007.10.008","article-title":"Diagnosis and Assessment of Pain Associated with Herpes Zoster and Postherpetic Neuralgia","volume":"9","author":"Dworkin","year":"2008","journal-title":"J. Pain"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Kawai, K., Gebremeskel, B.G.G., and Acosta, C.J. (2014). Systematic review of incidence and complications of herpes zoster: Towards a global perspective. BMJ Open, 4.","DOI":"10.1136\/bmjopen-2014-004833"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/cid\/ciq077","article-title":"Herpes Zoster Incidence Among Insured Persons in the United States, 1993\u20132006: Evaluation of Impact of Varicella Vaccination","volume":"52","author":"Leung","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1212\/WNL.0b013e3182a3516e","article-title":"The global epidemiology of herpes zoster","volume":"81","author":"Yawn","year":"2013","journal-title":"Neurology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.4065\/82.11.1341","article-title":"A Population-Based Study of the Incidence and Complication Rates of Herpes Zoster Before Zoster Vaccine Introduction","volume":"82","author":"Yawn","year":"2007","journal-title":"Mayo Clin. Proc."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1017\/S0950268801005921","article-title":"Epidemiology of varicella zoster virus infection in Canada and the United Kingdom","volume":"127","author":"Brisson","year":"2001","journal-title":"Epidemiol. Infect."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/2051013615599151","article-title":"Herpes zoster epidemiology, management, and disease and economic burden in Europe: A multidisciplinary perspective","volume":"3","author":"Johnson","year":"2015","journal-title":"Ther. Adv. Vaccines"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Marra, F., Chong, M., and Najafzadeh, M. (2016). Increasing incidence associated with herpes zoster infection in British Columbia, Canada. BMC Infect. Dis., 16.","DOI":"10.1186\/s12879-016-1898-z"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.puhe.2018.10.015","article-title":"Systematic review of the evidence on the epidemiology of herpes zoster: Incidence in the general population and specific subpopulations in Spain","volume":"167","author":"Mareque","year":"2019","journal-title":"Public Health"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Caputo, M., Horn, J., Karch, A., Akmatov, M.K., Becher, H., Braun, B., Brenner, H., Castell, S., Fischer, B., and Giani, G. (2019). Herpes zoster incidence in Germany\u2014An indirect validation study for self-reported disease data from pretest studies of the population-based German National Cohort. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-3691-2"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1056\/NEJMp058091","article-title":"Ageing, immunity, and the varicella-zoster virus","volume":"352","author":"Arvin","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Pan, C.X., Lee, M.S., and Nambudiri, V.E. (2022). Global herpes zoster incidence, burden of disease, and vaccine availability: A narrative review. Ther. Adv. Vaccines Immunother., 10.","DOI":"10.1177\/25151355221084535"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1016\/S0264-410X(02)00180-9","article-title":"Exposure to varicella boosts immunity to herpes-zoster: Implications for mass vaccination against chickenpox","volume":"20","author":"Brisson","year":"2002","journal-title":"Vaccine"},{"key":"ref_19","first-page":"1","article-title":"Prevention of herpes zoster: Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","author":"Harpaz","year":"2008","journal-title":"MMWR. Recomm. Rep."},{"key":"ref_20","unstructured":"Centers for Disease Control and Prevention (2011). Update on herpes zoster vaccine: Licensure for persons aged 50 through 59 years. MMWR Morb. Mortal. Wkly. Rep., 60, 1528."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1086\/653605","article-title":"Zoster vaccine: Current status and future prospects","volume":"51","author":"Oxman","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/cid\/cir970","article-title":"Efficacy, Safety, and Tolerability of Herpes Zoster Vaccine in Persons Aged 50\u201359 Years","volume":"54","author":"Schmader","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_24","unstructured":"Food and Drug Administration (2022, October 22). Shingrix [Package Insert], Available online: https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM581605.pdf."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults","volume":"372","author":"Lal","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_27","first-page":"339","article-title":"Comparison of analytical methods for cluster randomised trials: An example from a primary care setting","volume":"5","author":"Mollison","year":"2000","journal-title":"J. Epidemiol. Biostat."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/qhc.12.1.47","article-title":"Research designs for studies evaluating the effectiveness of change and improvement strategies","volume":"12","author":"Eccles","year":"2003","journal-title":"BMJ Qual. Saf."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"S429","DOI":"10.1093\/infdis\/jiab387","article-title":"Herpes zoster vaccines","volume":"224","author":"Harbecke","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1016\/j.vaccine.2019.07.004","article-title":"Long-term effectiveness of zoster vaccine live for postherpetic neuralgia prevention","volume":"37","author":"Klein","year":"2019","journal-title":"Vaccine"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Andrews, N., Stowe, J., Kuyumdzhieva, G., Sile, B., Yonova, I., De Lusignan, S., Ramsay, M., and Amirthalingam, G. (2020). Impact of the herpes zoster vaccination programme on hospitalised and general practice consulted herpes zoster in the 5 years after its introduction in England: A population-based study. BMJ Open, 10.","DOI":"10.1136\/bmjopen-2020-037458"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR. Morb. Mortal. Wkly. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/cid\/cis638","article-title":"Persistence of the Efficacy of Zoster Vaccine in the Shingles Prevention Study and the Short-Term Persistence Substudy","volume":"55","author":"Schmader","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Tricco, A.C., Zarin, W., Cardoso, R., Veroniki, A.-A., Khan, P., Nincic, V., Ghassemi, M., Warren, R., Sharpe, J.P., and Page, A.V. (2018). Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: Systematic review and network meta-analysis. BMJ, 363.","DOI":"10.1136\/bmj.k4029"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/S2666-7568(22)00039-3","article-title":"Post-licensure zoster vaccine effectiveness against herpes zoster and postherpetic neuralgia in older adults: A systematic review and meta-analysis","volume":"3","author":"Mbinta","year":"2022","journal-title":"Lancet Healthy Longev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"7231","DOI":"10.1016\/j.vaccine.2017.11.013","article-title":"Herpes zoster vaccine live: A 10 year review of post-marketing safety experience","volume":"35","author":"Willis","year":"2017","journal-title":"Vaccine"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1016\/j.vaccine.2020.03.054","article-title":"Safety of live attenuated herpes zoster vaccine in adults 70\u201379 years: A self-controlled case series analysis using primary care data from Australia\u2019s Medicine Insight program","volume":"38","author":"Totterdell","year":"2020","journal-title":"Vaccine"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Phillips, A., Glover, C., Leeb, A., Cashman, P., Fathima, P., Crawford, N., Snelling, T.L., Durrheim, D., and Macartney, K. (2021). Safety of live attenuated herpes zoster vaccine in Australian adults 70\u201379 years of age: An observational study using active surveillance. BMJ Open, 11.","DOI":"10.1136\/bmjopen-2020-043880"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Costa, E., Buxton, J., Brown, J., Templeton, K.E., Breuer, J., and Johannessen, I. (2016). Fatal disseminated varicella zoster infection following zoster vaccination in an immunocompromised patient. BMJ Case Rep., 2016.","DOI":"10.1136\/bcr-2015-212688"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1016\/j.vaccine.2018.05.078","article-title":"Live zoster vaccination in an immunocompromised patient leading to death secondary to disseminated varicella zoster virus infection","volume":"36","author":"Alexander","year":"2018","journal-title":"Vaccine"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"E1025","DOI":"10.1503\/cmaj.190270","article-title":"Disseminated varicella zoster virus infection after vaccination with a live attenuated vaccine","volume":"191","author":"Dubey","year":"2019","journal-title":"Can. Med. Assoc. J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/cid\/ciab125","article-title":"Recombinant Zoster Vaccine (Shingrix): Real-World Effectiveness in the First 2 Years Post-Licensure","volume":"73","author":"Izurieta","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/cid\/ciab121","article-title":"Effectiveness of the Recombinant Zoster Vaccine in Adults Aged 50 and Older in the United States: A Claims-Based Cohort Study","volume":"73","author":"Sun","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1016\/j.vaccine.2021.05.056","article-title":"Effectiveness of the recombinant zoster vaccine among Kaiser Permanente Hawaii enrollees aged 50 and older: A retrospective cohort study","volume":"39","author":"Sun","year":"2021","journal-title":"Vaccine"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/cid\/ciab130","article-title":"The Effectiveness of Recombinant Zoster Vaccine: Observations in the Wild","volume":"73","author":"Harpaz","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/aje\/kwr206","article-title":"Comparing shingles incidence and complication rates from medical record review and administrative database estimates: How close are they?","volume":"174","author":"Yawn","year":"2011","journal-title":"Am. J. Epidemiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.annepidem.2016.04.006","article-title":"Self-reported herpes zoster, pain, and health care seeking in the health and retirement study: Implications for interpretation of health care-based studies","volume":"26","author":"Hales","year":"2016","journal-title":"Ann. Epidemiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"91","DOI":"10.15585\/mmwr.mm6804a4","article-title":"Postlicensure safety surveillance of recombinant zoster vaccine (Shingrix)\u2014United States, October 2017\u2013June 2018","volume":"68","author":"Hesse","year":"2019","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1016\/j.vaccine.2019.11.058","article-title":"Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine","volume":"38","author":"Co","year":"2020","journal-title":"Vaccine"},{"key":"ref_51","unstructured":"Nelson, J.C., and Vaccine Safety Datalink (VSD) Update on Post-Licensure Safety Monitoring of Recombinant Zoster Vaccine (Shingrix) (2022, October 20). ACIP\u2019s 20 October 2020 Meeting Slides, Available online: https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2020-10\/ZosterVaccine-03-Nelson-508.pdf."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1001\/jamainternmed.2021.6227","article-title":"Risk of Guillain-Barr\u00e9 Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries","volume":"181","author":"Goud","year":"2021","journal-title":"JAMA Intern. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/oxfordjournals.aje.a115973","article-title":"Reassessment of the Association between Guillain-Barr\u00e9 Syndrome and Receipt of Swine Influenza Vaccine in 1976\u20131977: Results of a Two-State Study","volume":"133","author":"Safranek","year":"1991","journal-title":"Am. J. Epidemiol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Hanson, K.E., Goddard, K., Lewis, N., Fireman, B., Myers, T.R., Bakshi, N., Weintraub, E., Donahue, J.G., Nelson, J.C., and Xu, S. (2022). Incidence of Guillain-Barr\u00e9 Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink. JAMA Netw. Open, 5.","DOI":"10.1001\/jamanetworkopen.2022.8879"},{"key":"ref_55","unstructured":"(2022, October 20). U.S. Food and Drug Administration. FDA Requires a Warning about Guillain-Barr\u00e9 Syndrome (GBS) Be Included in the Prescribing Information for Shingrix\u00ae, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/fda-requires-warning-about-guillain-barre-syndrome-gbs-be-included-prescribing-information-shingrix."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/cid\/ciu918","article-title":"Long-term Persistence of Zoster Vaccine Efficacy","volume":"60","author":"Morrison","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/cid\/ciw854","article-title":"Effectiveness and Duration of Protection Provided by the Live-attenuated Herpes Zoster Vaccine in the Medicare Population Ages 65 Years and Older","volume":"64","author":"Izurieta","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/aje\/kwx245","article-title":"Long-Term Effectiveness of the Live Zoster Vaccine in Preventing Shingles: A Cohort Study","volume":"187","author":"Baxter","year":"2017","journal-title":"Am. J. Epidemiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/infdis\/jiw047","article-title":"Declining Effectiveness of Herpes Zoster Vaccine in Adults Aged \u226560 Years","volume":"213","author":"Tseng","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1093\/cid\/ciab629","article-title":"The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70","volume":"74","author":"Boutry","year":"2021","journal-title":"Clin. Infect. Dis."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/12\/2667\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:29:04Z","timestamp":1760146144000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/12\/2667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,29]]},"references-count":60,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["v14122667"],"URL":"https:\/\/doi.org\/10.3390\/v14122667","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,29]]}}}